L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial

Matthias Kraft, Kathleen Kraft, Simone Gärtner, Julia Mayerle, Peter Simon, Eckhard Weber, Kerstin Schütte, Jens Stieler, Heide Koula-Jenik, Peter Holzhauer, Uwe Gröber, Georg Engel, Cornelia Müller, You-Shan Feng, Ali Aghdassi, Claudia Nitsche, Peter Malfertheiner, Maciej Patrzyk, Thomas Kohlmann and Markus M Lerch

Abstract

Background: Cachexia, a >10% loss of body-weight, is one factor determining the poor prognosis of pancreatic cancer. Deficiency of L-Carnitine has been proposed to cause cancer cachexia.

Findings: We screened 152 and enrolled 72 patients suffering from advanced pancreatic cancer in a prospective, multi-centre, placebo-controlled, randomized and double-blinded trial to receive oral L-Carnitine (4 g) or placebo for 12 weeks. At entry patients reported a mean weight loss of 12 ± 2.5 (SEM) kg. During treatment body-mass-index increased by 3.4 ± 1.4% under L-Carnitine and decreased (−1.5 ± 1.4%) in controls (p < 0.05). Moreover, nutritional status (body cell mass, body fat) and quality-of-life parameters improved under L-Carnitine. There was a trend towards an increased overall survival in the L-Carnitine group (median 519 ± 50 d versus 399 ± 43 d, not significant) and towards a reduced hospital-stay (36 ± 4d versus 41 ± 9d, n.s.).

Conclusion: While these data are preliminary and need confirmation they indicate that patients with pancreatic cancer may have a clinically relevant benefit from the inexpensive and well tolerated oral supplementation of L-Carnitine.

Keywords: Pancreatic adenocarcinoma, L-Carnitine, Quality of life, Survival, Cancer cachexia, Fatigue syndrome

Background

Adenocarcinoma of the pancreas is highly resistant to chemo- or radiotherapy [1], has a 5-year survival rate of only 4% and ranks as fourth leading cause of cancer death [2–4]. One reason contributing to this high mortality is cancer cachexia, defined as an unintended weight loss of more than 10% in 6 months, which is present in more than 80% of pancreatic cancer patients [5]. Cancer cachexia is also a predictor for reduced quality of life, increased mortality, and poor response to therapy [6–10]. A deficiency of L-Carnitine has been proposed to be an underlying cause of cancer cachexia [11] and tumor associated fatigue [12–14]. Although L-Carnitine can be generated via endogenous conversion from lysine and methionine, 75% of the required levels are provided from food sources. In vitro studies in human tumor cell lines have shown a positive effect of L-Carnitine regarding the inhibition of apoptosis and DNA-damage [15]. On the other hand, L-Carnitine is well known for its potential to modulate the inflammatory response mechanisms, which is known to play the predominant role in the generation of cancer cachexia, especially in pancreatic tumor patients [16]. We therefore conducted a multicentre trial to investigate the role of oral L-Carnitine supplementation on cancer cachexia in pancreatic cancer (CARPAN).

Methods

Patients from 4 participating tertiary referral centers were considered eligible for inclusion when they had histologically proven, advanced and irresectable adenocarcinoma
of the pancreas (UICC Stage IV), had a Karnofsky performance status of >60 and declared their written informed consent to participate. The CARPAN protocol was approved by the ethics committee of Greifswald University (Reg.Nr.IIIUV73/05) and registered at clinicaltrials.gov (NCT01330823) and under ISRCTN83465351. Patients were recruited regardless of concomitant or scheduled chemotherapy. Exclusion criteria were liver failure, a second malignancy, treatment with omega-3-fatty acids and the presence of a mental disorder precluding informed consent. From May 2006 until October 2009 a total of 152 patients were screened and 72 enrolled in the study (Figure 1). Reasons for non-enrollment were mostly due to poor performance status or withheld consent. Patients were randomized (sequential series of 4 per block, sealed envelopes, computer generated randomization code) to receive either an oral liquid formulation of L-Carnitine (4 g/d, obtained from Lonza, Basel, CH) or identically formulated placebo with follow up visits at 6 and 12 weeks after entry. Compliance was tested by determining serum L-Carnitine levels by Tandem-Mass-Spectrometry (normal range between 40–60 μmol/l) (ABI 2000, Perkin-Elmer, Turku, SF) [17]. L-Carnitine deficiency is generally believed to occur below 30 μmol/l, albeit data on functional relevance are controversially discussed [18]. At every study visit adverse events and body mass index (BMI) were recorded and bioelectrical impedance analysis (BIA-Nutrigard-M, Darmstadt, Germany) was used to determine body composition [19]. For evaluation of quality of life we used the EORTC-QLQ-C30 questionnaire with a pancreatic cancer specific module PAN26 [20] and for fatigue the Brief Fatigue Inventory (BFI) questionnaire [21]. Survival time in days was calculated from time of diagnosis to death. Sample size calculation was based on previous studies investigating the effect of L-Carnitine on inflammatory markers [22], with TNFα level differences as primary endpoint, and resulted in a recruitment goal of 90 patients (45 per treatment arm) for a statistical power of 90% with an error probability of <5%. After a prescheduled interim analysis for sample size recalculation of 72 blinded datasets showed a wide variation of the standard errors for inflammatory markers a recruitment of 554 patients (277 per group) would have been necessary. Since this goal was unattainable the study was closed after enrolment of 72 patients and the data were unblinded for statistical analysis.

Data are presented as means ± SEM and 95% confidence intervals where appropriate. Statistical analysis for intention-to-treat and per-protocol analysis was done

![Figure 1 Flow chart of the trial.](http://www.nutritionj.com/content/11/1/52)
by Student’s t test and Pearson’s chi-square test for parametric and Mann–Whitney-U-Test for non-parametric analysis. Quality of life data were analyzed using ANOVA. Results were considered significant when p was <0.05.

**Results**

Patient characteristics are given in Table 1 and showed no statistical difference between both groups at enrolment. At entry 88% of patients in the placebo and 92% of patients in the L-Carnitine group received chemotherapy. There was no statistically significant difference between both groups (p < 0.05). 90% of the patients reported a weight loss of >10% during the previous 6 month. This observation is in line with previous reports on cancer cachexia [5]. 26 patients completed the entire follow up period and premature drop-out was due to death (n = 11), deteriorating health (n = 9), nausea (n = 8), excessive demand (n = 5), diarrhea (n = 2) or miscellaneous symptoms (n = 7). Drop out rates and reasons were not different between both treatment arms. Oral supplementation of L-Carnitine substantially increased L-Carnitine serum plasma levels up to 60% of the basic value at week 6 (p < 0.009) in the L-Carnitine group (Figure 2), while a constant decline of L-Carnitine plasma levels was evident during the observation period in the placebo group. This might be related to tumor effects and / or due to concomitant chemotherapy. L-Carnitine supplementation was well tolerated. Side effects did not differ significantly in comparison with placebo group (predominantly nausea, vomiting, and diarrhoea) and, whenever they occurred, may have been caused by concomitant chemotherapy.

Patients on L-Carnitine treatment gained weight (BMI increase of 3.4% ± 1.35) whereas patients on placebo did not (BMI reduction of 1.5% ± 1.4, p < 0.018). After 12 weeks of therapy the difference amounted to 4.9% ± 1.9 (Figure 3) between groups. BLA revealed that this improvement was due to increases in body cell mass (BCM, p < 0.013) and body fat (BF, p < 0.041). CRP, albumin, leukocyte count and CA19-9 remained unaffected (data not shown). Regarding quality of life (EORTC-QLQ-C30/PAN26) the only significant changes were improvement in cognitive function (at enrolment 81.0 ± 21.5

| Parameter | L-Carnitine (n = 38) | Placebo (n = 34) |
|-----------|----------------------|------------------|
| gender    | male                 | 20 (52.6%)       | 23 (67.6%)      |
|           | female               | 18 (47.4%)       | 11 (32.4%)      |
| mean age  |                      | 64.4 ± 1.67      | 64.4 ± 1.65     |
| Karnofsky performance status | 76.8 ± 1.87 | 80.0 ± 2.16 |
| **Nutritional Status**          |                     |                  |
| normal BMI (kg/m²)             | 28.0 ± 1.01         | 30.1 ± 0.84     |
| baseline visit BMI (kg/m²)     | 24.7 ± 0.65         | 24.9 ± 0.89     |
| Phase angle (°)                | 4.4 ± 0.16          | 4.4 ± 0.17      |
| Weight loss* present           | 34 (89.5%)          | 31 (91.2%)      |
| meanweight loss (kg)*          | 11.4 ± 1.28         | 12.3 ± 1.56     |
| Nutritional support none       | 20 (52.6%)          | 21 (61.8%)      |
| Oral                               | 14 (36.8%)          | 9 (26.5%)       |
| Parenteral nutrition             | 4 (10.5%)           | 4 (11.7%)       |
| ECM/BCM index **                | 1.5 ± 0.11          | 1.4 ± 0         |
| Cell percentage (%)             | 41.8 ± 1.22         | 42.70 ± 1.21    |
| chemotherapy (n) 35 (92%) 30 (88%) |                  |

**Laboratory values**

| Parameter | L-Carnitine (μmol/l) | Placebo (μmol/l) |
|-----------|----------------------|------------------|
| L-Carnitine level | 25.3 ± 2.29 | 24.8 ± 2.11 |
| Albumine (g/l)    | 33.8 ± 1.09       | 33.7 ± 1.20     |
| CRP (mg/l)        | 31.3 ± 6.55       | 45.5 ± 10.39    |
| Leucocytes (Gpt/l) | 8.3 ± 0.83 | 6.9 ± 0.46     |
| CA 19–9 (U/ml)    | 14,095 ± 32,572   | 18,345 ± 35,950 |

No statistically significant differences were observed between L-Carnitine and placebo group.

*weight loss during the last 6 month.

**ECM/BCM-Index, Extra-Cellular-Mass/Body-Cell-Mass-Index.
in L-Carnitine group, 86.1 ± 17.2 in placebo group; after 6 weeks L-Carnitine group 0.30 versus −0.13 in the placebo group, \( p < 0.034 \), improvement of global health status (at enrolment 53.6 ± 19.5 in L-Carnitine group, 65.3 ± 17.7 in placebo group; after 12 weeks L-Carnitine group 0.76 versus −0.32 in the placebo group, \( p < 0.041 \)) and reduction in gastrointestinal symptoms (at enrolment 29.8 ± 32.1 in L-Carnitine group, 19.4 ± 24.5; in the placebo group; after 12 weeks L-Carnitine group −0.35 versus 0.78 in the placebo group; \( p < 0.033 \)). Differences in fatigue (moderate/severe, >4 on BFI), present in 28.6% of L-Carnitine patients versus 41.7% in the placebo group, were not statistically significant, nor was the survival benefit (Figure 2, median 519 ± 50d versus 399 ± 43d with placebo), and the reduction in length of hospital stay (36 ± 4d versus 41 ± 9d with placebo).

**Conclusion**
Cancer cachexia and malnutrition are associated with an increased risk of surgical complications and higher
toxicity levels of chemotherapy. Quality of life and overall survival of colon cancer patients can improve under early nutritional intervention [23]. L-Carnitine is critical for energy generation by mitochondrial β-oxidation and was found depleted under chemotherapy [24–26]. Its oral supplementation can normalize nutritional L-Carnitine deficiency [27,28] and reduce chemotherapy related side effects [29,30]. We therefore tested whether oral L-Carnitine supplementation has a clinical benefit in patients with advanced pancreatic cancer and found that L-Carnitine can reduce malnutrition, increase bodyweight and improve body composition.

When we planned and designed the study no persuasive data for clinical endpoints existed and we had to base the initial power calculations on inflammatory markers in humans under L-Carnitine treatment. While this study must be regarded as preliminary because inflammatory markers were found to be an unsuitable primary endpoint in our setting, the CARPAN trial provides the basis for a robust sample size calculation: a conclusive study of L-Carnitine benefits ought to enrol 148 patients in each arm to show a survival benefit with 90% power, and would need 157 patients in each arm to demonstrate an improvement in tumor fatigue. The presently available data show a benefit of L-Carnitine supplementation on body weight, body composition and some aspects of quality-of-life, even though it was underpowered to determine the statistical significance of other secondary endpoints. While the loss of significant changes in BCM at week 12 and a rapid increase in body fat between week 6 and 12 was an unexpected finding it might be explained by the underlying progressive tumor disease leading to changes in body composition, irrespective of gain of weight and due to reduced physical activity and progressive sarcopenia. Both are common findings in pancreatic tumors. In this context it is important to note, that the direct influence of L-Carnitine on tumor growth has not been measured in this study and is beyond the scope of this work. Future studies are needed to address this question as only recently L-Carnitine has been reported to modify apoptosis and DNA-damage in tumor cell lines of the brain via CPT-1 C [15].

The CARPAN trial could suggest that the clinical benefit of an inexpensive and very well tolerated oral L-Carnitine supplementation may reach the clinical benefit level previously shown for palliative Gemcitabine chemotherapy [31] in pancreatic cancer patients.

Abbreviations
BIA: Bioelectrical impedance analysis; BF: Body fat; BFI: Brief fatigue inventory; BMI: Body mass index; BCM: Body cell mass; CPT: Carnitine palmitoyltransferase; CRP: C-reactive protein; ECM: Extra cellular mass; SEM: Standard error of the mean; TNFα: Tumor necrose factor α.

Competing interests
The authors declare that they have no competing interests.

Acknowledgement
This study was supported by the Alfred-Krupp-von-Bohlen-und-Halbach- Foundation (Graduate Schools Tumour Biology and Free Radical Biology), the Deutsche Krebshilfe/ Dr. Mildred-Scheel-Stiftung (109102), the Deutsche Forschungsgemeinschaft (DFGgefR840-ES/E4, MA 4115/1–2/5, NI 12971/1–1), the Federal Ministry of Education and Research (BMBF-ANI-MED 03152061A and BMBF 0314107) and the European Union (EU-FFP-7: EPC-TM and EU-FFP7–REGPOT-2010-1). KK and SG both received a Gerhard-Domagk-Stipendium of Greifswald University Medicine made possible through unrestricted educational grants from Medinal GmbH, Greven, Germany, Fresenius Kabi Germany GmbH Bad Homburg, Germany and Nutricia GmbH, Erlangen, Germany. L-Carnitine bulk compound was kindly provided by Lonza Ltd., Basel, Switzerland.

Author details
1. Department of Medicine A, University Medicine Greifswald, Friedrich Löffler Straße 23a, Greifswald 17475, Germany. 2. Department for Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University Magdeburg, Magdeburg, Germany. 3. Charité Universitätsmedizin Berlin, Campus Virchow-Clinic, Medical Clinic Hematology/Oncology, Berlin, Germany. 4. Veramed Clinic, Brannenburg, Germany. 5. Academy of Micronutrient Medicine, Essen, Germany. 6. University Pharmacy, University Medicine Greifswald, Greifswald, Germany. 7. Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany. 8. Department of Surgery, University Medicine Greifswald, Greifswald, Germany. 9. Institute of Community Medicine, University Medicine of Greifswald, Greifswald, Greifswald, Germany.

Authors’ contribution
All authors of the study substantially contributed to conception, design, acquisition and analysis of data and interpretation of the study. KK, MK, MML, UG, and PHI designed research, SG, JM, PS, KS, JS, HK, AA, CN, PM and MP conducted research, JR, MF, HV and CDH provided essential materials, CM, GE, EW, YSF and TK analysed data, KK, MK and MML wrote paper, KK, MK and MML had primary responsibility for final content. All authors read and approved the final manuscript and disclose any financial or personal relationships.

Received: 16 February 2012 Accepted: 6 July 2012
Published: 23 July 2012

Reference
1. Rocha-Lima CM: New directions in the management of advanced pancreatic cancer: a review. Anticancer Drugs 2008, 19:435–446.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15–38.
3. DiMaggio EP, Reber HA, Temporao MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999, 117:1464–1484.
4. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304:1073–1081.
5. Bachmann J, Ketterer K, Marsch C, Fechtner K, Krakowski-Roosen H, Büchler GE, EW, YSF and TK analysed data, KK, MK and MML wrote paper, KK, MK and MML had primary responsibility for final content. All authors read and approved the final manuscript and disclose any financial or personal relationships.

Published: 23 July 2012

Reference
1. Rocha-Lima CM: New directions in the management of advanced pancreatic cancer: a review. Anticancer Drugs 2008, 19:435–446.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15–38.
3. DiMaggio EP, Reber HA, Temporao MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999, 117:1464–1484.
4. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304:1073–1081.
5. Bachmann J, Ketterer K, Marsch C, Fechtner K, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME: Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer 2009, 9:255.
6. Pelzer U, Arnold D, Govercin M, Streis J, Doerken B, Riess H, Oettle H: Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer 2010, 10:86.
7. Uomog, Gallucci F, Rabitti PG: Anorexia-cachexia syndrome in pancreatic cancer: recent development in research and management. JOP 2006, 7:157–162.
8. Ockenga J, Valentini L: Review article: anorexia and cachexia in gastrointestinal cancer. Aliment Pharmacol Ther 2005, 22:583–594.
9. Bozzetti F: Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support Care Cancer 2009, 17:279–284.
10. Cohen SI, Pinover WH, Watson JC, Metropol NJ: Pancreatic cancer. Cur Treat Options Oncol 2000, 1:375–386.
11. Malaguarnera M, Risino C, Gargante MP, Tomassello AV, Costanzo M, Cannizzaro MA, Costanzo M, Cannizzaro MA: Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J Gastroenterol 2006, 12:4541–4545.

12. Graziano F, Biondi R, Catalano V, Silva R, Rovidati S, Mencatini E, Ferraro B, Canestrini F, Baldelli AM, Deg A, et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anemic cancer patients. Br J Cancer 2002, 86:1854–1857.

13. Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: inevitable, unimportant and untestable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000, 11:971–975.

14. Schwartz AL, Nall LM, Chen S, Meek P, Barsewick AM, King ME, Jones LS. Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest 2000, 18:11–19.

15. Zaugg K, Yao Y, Reilly PT, Kannan K, Karash R, Mason J, Huang P, Sawyer SK, Fueth B, Faubert B, et al. Carnitine palmitoyltransferase 1 C promotes cell survival and tumourgrowth under conditions of metabolic stress. Genes Dev 2011, 25:1041–51.

16. Liu S, Zhang QZ, Chen Q, Liu B, Wu JP, Zhu L. L-Carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmitoyl transferase. Cancer Biol Ther 2011, 12:125–30.

17. Kodo N, Millington DS, Norwood DL, Roe CR. Quantitative assay of free and total carnitine using tandem mass spectrometry. Clin Chim Acta 1990, 186:383–390.

18. Rebouche Cj. Carnitine function and requirements during the life cycle. FASEB J 1992, 6:3379–3386.

19. Bosy-Westphal A, Danielzik S, Dorhofer RP, Later W, Weise S, Muller MJ. Phase angle from bioelectrical impedance analysis: population reference values by age, sex, and body mass index. JPEN J Parenter Enter Nutr 2006, 30:209–316.

20. Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, Beger HG, Birk D, Buchler MW, Derenets C, et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer Qol. questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study group on Quality of Life. Eur J Cancer 1999, 35:939–941.

21. Radbruch L, Sabatowski R, Elsner F, Everts J, Mendoza T, Cleeland C. Validation of the German version of the brief fatigue inventory. J Pain Symptom Manage 2003, 25:449–458.

22. Grazig G, Meriggioli M. Can the treatment with L-carnitine improve the inflammation in chronic hemo dialysis patients? G Ital Nefrol 2004, 21(Suppl 30):S207–S208.

23. Nitenberg G, Raynard B. Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol 2000, 34:137–168.

24. Dodson L, Sahjan D, Krauss S, Hanno WN. Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance. J Am Coll Nutr 1989, 8:133–142.

25. Manzelli A, D’Iddio S, Biondi R, Graziano F, Lippe P, Calvani M. Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. Cancer Chemother Pharmacol 2007, 60:19–26.

26. Lancaster CS, Hu C, Franke RM, Filipski KK, Orwick SJ, Chen Z, Zuo Z, Loosw J, Sparreboom A. Cisplatin-induced down regulation of OCTN2 affects carmitine wasting. Cln Cancer Res 2010, 16:4789–4799.

27. Lebrun C, Alchaar H, Candito M, Boury V, Chatel M. Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler 2006, 12:321–324.

28. Cruciani RA, Dvorin E, Homel P, Culliney B, Malamud S, Lapin J, Portenoy RK, Esheban-Cruciani N. L-carnitine supplementation in patients with advanced cancer and carmitine deficiency: a double-blind, placebo-controlled study. J Pain Symptom Manage 2009, 37:622–631.

29. Pisano C, Vesci L, Milazzo FM, Guglielmi MB, Formenti R, Barbarino M, D’Incalci M, Zucchetti M, Petrangolini G, Tortoreto M, et al. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine. Cln Cancer Res 2010, 16:3944–3953.

30. Haschke M, Vitins T, Lude S, Todesco L, Novakova K, Herrmann R, Krahnenhul S. Urinary excretion of carmitine as a marker of proximal tubular damage associated with platin-based anti neoplastic drugs. Nephrol Dial Transplant 2010, 25:426–433.

31. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Stornoli AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer a randomized trial. J Clin Oncol 1997, 15:2423–2431.